All prohibited substances in this class are non-Specified Substances.

The following substances, and other substances with similar chemical structure or similar biological effect(s), are prohibited:

1. ERYTHROPOIETINS (EPO) AND AGENTS AFFECTING ERYTHROPOIESIS, INCLUDING, BUT NOT LIMITED TO:

1.1 ERYTHROPOIETIN-RECEPTOR AGONISTS, E.G.

  • Darbepoetins (dEPO)
  • Erythropoietins (EPO)
  • EPO-based constructs [e.g. EPO-Fc, methoxy polyethylene glycol-epoetin beta (CERA)]
  • EPO-mimetic agents and their constructs (e.g. CNTO-530, peginesatide)

1.2 HYPOXIA-INDUCIBLE FACTOR (HIF) ACTIVATING AGENTS, E.G.

  • Cobalt
  • Daprodustat (GSK1278863)
  • IOX2
  • Molidustat (BAY 85-3934)
  • Roxadustat (FG-4592)
  • Vadadustat (AKB-6548)
  • Xenon

1.3 GATA INHIBITORS, E.G.

  • K-11706

1.4 TRANSFORMING GROWTH FACTOR -BETA (TGF-Β) SIGNALING INHIBITORS, E.G.

  • Luspatercept
  • Sotatercept

1.5 INNATE REPAIR RECEPTOR AGONISTS, E.G.

  • Asialo EPO
  • Carbamylated EPO (CEPO)

2. PEPTIDE HORMONES AND THEIR RELEASING FACTORS

2.1 CHORIONIC GONADOTROPHIN (CG) AND LUTEINIZING HORMONE (LH) AND THEIR RELEASING FACTORS IN MALES, E.G.

  • Buserelin 
  • Deslorelin
  • Gonadorelin
  • Goserelin
  • Leuprorelin
  • Nafarelin
  • Triptorelin

2.2 CORTICOTROPHINS AND THEIR RELEASING FACTORS, E.G.

  • Corticorelin

2.3 GROWTH HORMONE (GH), ITS ANALOGUES AND FRAGMENTS, INCLUDING, BUT NOT LIMITED TO:

  • growth hormone analogues, e.g. lonapegsomatropin, somapacitan and somatrogon
  • growth hormone fragments, e.g. AOD-9604 and hGH 176-191

2.4 GROWTH HORMONE RELEASING FACTORS, INCLUDING, BUT NOT LIMITED TO:

  • growth hormone-releasing hormone (GHRH) and its analogues (e.g. CJC-1293, CJC-1295, sermorelin and tesamorelin)
  • growth hormone secretagogues (GHS) and its mimetics [e.g. lenomorelin (ghrelin), anamorelin, ipamorelin, macimorelin and tabimorelin]
  • GH-releasing peptides (GHRPs) [e.g. alexamorelin, GHRP-1, GHRP-2 (pralmorelin), GHRP-3, GHRP-4, GHRP-5, GHRP-6, and examorelin (hexarelin)]

3. GROWTH FACTORS AND GROWTH FACTOR MODULATORS

INCLUDING, BUT NOT LIMITED TO:

  • Fibroblast growth factors (FGFs)
  • Hepatocyte growth factor (HGF)
  • Insulin-like growth factor 1 (IGF-1) and its analogues
  • Mechano growth factors (MGFs)
  • Platelet-derived growth factor (PDGF)
  • Thymosin-β4 and its derivatives e.g. TB-500
  • Vascular endothelial growth factor (VEGF)

    and other growth factors or growth factor modulators affecting muscle, tendon or ligament protein synthesis/degradation, vascularisation, energy utilization, regenerative capacity or fibre type switching.

WKSF Sponsor for 2022 Anti-Doping Campaign